Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL7089633 | 0.89 | DRD4 (0.46) | MCHR2MCHR1CACNA1GOPRM1SMN1; SMN2 | |
| SCHEMBL7089635 | 0.87 | DRD4 (0.46) | MCHR2MCHR1CACNA1GSMN1; SMN2LMNA | |
| SCHEMBL6807533 | 0.86 | MAPK14 (0.53) | MCHR2MCHR1CACNA1GSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL5578415 | 0.86 | ACHE (0.57) | MCHR2MCHR1CACNA1GOPRM1SMN1; SMN2 | |
| SCHEMBL1980829 | 0.82 | HDAC6 (0.53) | SMN1; SMN2MAPTHDAC6 | |
| Hydrochloric Acid SCHEMBL7087753 | 0.81 | MAPK14 (0.49) | MCHR2MCHR1CACNA1GSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL5578392 | 0.81 | ACHE (0.60) | MCHR2MCHR1CACNA1GSMN1; SMN2LMNA | |
| SCHEMBL27014528 | 0.80 | CCR3 (0.70) | MCHR2MCHR1CACNA1GSMN1; SMN2LMNA | |
| SCHEMBL9386113 | 0.78 | ALDH1A1 (0.69) | MCHR2MCHR1SMN1; SMN2HTR1AMAPT | |
| SCHEMBL6802605 | 0.78 | DRD4 (0.56) | MCHR1CACNA1GSMN1; SMN2HTR1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2007-10-04 | — | — | US | disclosed |
| US-20040053826-A1 | Uses of polypeptides | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1308513-A1 | USE OF POLYPEPTIDE | Takeda Chemical Industries, Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232538-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | MCHR2 54/4885MCHR1 38/4885CACNA1G 1568/4885 |
| US-20040053826-A1 | Uses of polypeptides | NPSR1, SCTR, GRPR | MCHR2 54/4885MCHR1 38/4885CACNA1G 1568/4885 |
| US-20030207863-A1 | Preventives and remedies for central nervous system diseases | UTS2R, PRSS12, CTSA | MCHR2 348/4885MCHR1 581/4885CACNA1G 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.